**Curriculum Vitae** (abridged)

**Date:** July 15, 2026

**Name:** Thomas J. Hwang

**Office Address:** [redacted]

**Education:**

| | | |
|---|---|---|
| M.D. (*summa cum laude*) | Medicine | Harvard Medical School |
| A.B. (*cum laude*) | Biomedical Innovation | Harvard University |

**Faculty Academic Appointments:**

| | | | |
|---|---|---|---|
| 2026 - | Assistant Professor | Medicine | Brigham and Women's Hospital |

**Employment and Other Professional Positions:**

| | | |
|---|---|---|
| 2026 - | Visiting Senior Fellow | London School of Economics, London, UK |
| 2022-2026 | Internship in General Surgery; Residency in Urologic Surgery | Brigham and Women's Hospital |
| 2016, 2017-8 | Visiting Expert | European Medicines Agency |
| 2017-2018 | Research Associate | Program On Regulation, Therapeutics, And Law (PORTAL), Brigham and Women's Hospital |
| 2015-2016 | Associate, Healthcare Ventures | Bain Capital |
| 2014-2015 | Analyst | Blackstone Group, London, UK |

**Committee Service:**

**International**

| | | |
|---|---|---|
| 2023-2027 | ESMO Magnitude of Clinical Benefit Scale Working Group | European Society for Medical Oncology (ESMO) |

**National**

| | | |
|---|---|---|
| 2019-2021 | FDA-Harvard Working Group on Relevant Cancer Molecular Targets | Food and Drug Administration (FDA) |

**Regional/Local**

| | | |
|---|---|---|
| 2024-2025 | Committee on Publications | Massachusetts Medical Society |
| 2021-2022 | Medical School Admissions Committee | Harvard Medical School |

**Editorial Activities:**

**Ad hoc Reviewer**

British Medical Journal
JAMA
JAMA Internal Medicine
JAMA Oncology
New England Journal of Medicine

**Honors and Prizes:**

| | | | |
|---|---|---|---|
| 2014 | Hoopes Prize | Harvard College | Academic excellence |
| 2016 | Finalist, 30 Under 30 in Science and Healthcare | Forbes | Leadership |
| 2022 | Leon Reznick Prize | Harvard Medical School | Academic excellence |
| 2022 | Summa cum laude | Harvard Medical School | 21st recipient in school history |
| 2023 | STAT Wunderkind | STAT/Boston Globe | Named one of top 30 young researchers in the country |

## Report of Funded Projects

**Funding Information:**

| | |
|---|---|
| 2018-2021 | Swiss Cancer Research Foundation, Co-Principal Investigator<br>"Comparative analysis of clinical benefit and reimbursement of cancer medicines in the USA, Switzerland, and European Union" |
| 2020-2021 | National Institute for Health Care Management, Co-Principal Investigator<br>"Impact of consolidation on prescription drug pricing and access" |
| 2022-2023 | Washington Center for Equitable Growth, Co-Investigator (PI: Profs Maini/Feng)<br>"Market competition and pharmaceutical mergers and acquisitions: impact on pricing and access" |
| 2022-2025 | Kaiser Permanente Institute for Health Policy, Co-Principal Investigator<br>"Therapeutic value and reimbursement of new medicines in the United States and Europe" |
| 2026- | Arnold Ventures, Co-Investigator (PI: Dr. Kesselheim)<br>"Shaping a new era for US prescription drug policy: optimizing evidence, accessibility, regulation, and innovation" |

## Report of Regional, National and International Invited Teaching and Presentations

***No presentations sponsored by outside entities.***

**Regional/National**

| | |
|---|---|
| 2016 | "Global infectious diseases: new challenges and solutions" (Oral Presentation)<br>American Law and Medicine Annual Symposium, Boston University School of Law, Boston, MA |
| 2017 | "Transparency in health and health care" (Oral Presentation)<br>Harvard Law School, Health Law Policy, Biotechnology, and Bioethics, Cambridge, MA |
| 2022 | "Reforming the World Health Organization's Essential Medicines List" (Oral Presentation)<br>Harvard Center for Bioethics Symposium, Boston, MA |
| 2023 | "Trends in Medicare Part D Spending on Mirabegron and Policy Impacts" (Oral Presentation)<br>American Urologic Association (AUA), Chicago, IL |

**International**

| | |
|---|---|
| 2018 | "Clinical benefit of cancer drugs and health technology assessment in Europe" (Oral Presentation)<br>European Society for Medical Oncology (ESMO), Munich, Germany |
| 2024 | "Medicare Part D spending and implications of the Inflation Reduction Act" (Invited Lecture)<br>London School of Economics, Health Policy, London, United Kingdom |
| 2024 | "Increasing ESMO-MCBS awareness and adoption in USA" (Committee Presentation)<br>European Society for Medical Oncology (ESMO), Barcelona, Spain |
| 2025 | "Clinical benefit of cancer drugs in the curative setting and HTA decisions" (Oral Presentation)<br>European Society for Medical Oncology (ESMO), Berlin, Germany |

**Recognition:**

**Research Cited in Government Policy**

White House Office of Management and Budget (rulemaking and regulatory analysis)
European Commission (medical device regulation reform)
MedPAC and Centers for Medicare and Medicaid Services (pharmaceutical payment reform)
Government Accountability Office (priority review voucher program)
State of Massachusetts, Medicaid program (value-based purchasing of medicines)

## Report of Scholarship

**Research Investigations** *(selected)*

1. **Hwang TJ**, Bourgeois FT, Seeger JD. Drug safety in the digital age. *New England Journal of Medicine* 2014;370(26):2460-2462.

2. **Hwang TJ**, Carpenter D, Kesselheim AS. Target small firms for antibiotic innovation. *Science* 2014;344(6187):967-969.

3. **Hwang TJ**, Carpenter D, Kesselheim AS. Assessment of US pathway for approving medical devices for rare conditions. *BMJ* 2014;348:g217.

4. **Hwang TJ**, Kesselheim AS, Bourgeois FT. Postmarketing trials and pediatric device approvals. *Pediatrics* 2014;133(5):e1197-1202.

5. **Hwang TJ**, Avorn J, Carpenter D, Kesselheim AS. Quantifying the Food and Drug Administration's rulemaking delays highlights the need for transparency. *Health Aff* 2014;33(2):309-315.

6. **Hwang TJ**, Hooper DC. Association between fluoroquinolone resistance and resistance to other antimicrobial agents among *E. coli* urinary isolates in the outpatient setting: A national cross-sectional study. *Journal of Antimicrobial Chemotherapy* 2014;69(6):1720-1722.

7. **Hwang TJ**, Wares DF, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. *Int J Tuberc Lung Dis* 2013;17(10):1257-66.

8. **Hwang TJ**, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, Nunn P, Jaramillo E, Keshavjee S, Wares DF. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. *BMJ Open* 2014;4(1):e004143.

9. **Hwang TJ**, Gibbs KA, Podolsky SH, Linder JA. Antimicrobial stewardship and public knowledge of antibiotics. *Lancet Infect Dis* 2015;15(9):1000-1001.

10. Kesselheim AS, **Hwang TJ**, Franklin JM. Two decades of new drug development for central nervous system disorders. *Nature Reviews Drug Discovery* 2015;14(12):815-816.

11. **Hwang TJ**, Kesselheim AS. Vaccine pipeline has grown over the past two decades with more early-stage trials from small and medium-sized companies. *Health Aff* 2016;35(2):219-226.

12. **Hwang TJ**, Carpenter D, Lauffenburger JL, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. *JAMA Intern Med* 2016;176(12): 1826-33.

13. **Hwang TJ**, Kesselheim AS. Public referendum on drug prices in the US. *BMJ* 2016;355:i5657.

14. **Hwang TJ**, Sokolov E, Franklin JM, Kesselheim AS. Comparison of rates of safety issues and reporting of trial outcomes for medical devices approved in the European Union and United States: cohort study. *BMJ* 2016;353:i3323.

15. **Hwang TJ**, Lauffenburger JL, Franklin JM, Kesselheim AS. Temporal trends and factors associated with cardiovascular drug development, 1990 to 2012. *JACC: Basic to Translational Science* 2016;1(5):301-8.

    Fiuzat M, Stockbridge N, Califf RM. Resourcing drug development commensurate with its public health importance. *JACC Basic Transl Sci* 2016;1(5):309-312. [Editorial]

16. Davies BJ, **Hwang TJ**, Kesselheim AS. Ensuring access to injectable generic drugs: intravesical BCG for bladder cancer. *New England Journal of Medicine* 2017;376(5):1401-3.

17. **Hwang TJ**, Franklin JM, Kesselheim AS. Effect of US Food and Drug Administration's cardiovascular safety guidance on diabetes drug development. *Clin Pharmacol Ther* 2017;102(2):290-296.

    Honig P, Terzic A. Affairs of the heart: Innovation in cardiovascular research and development. *Clin Pharmacol Ther* 2017;102(2):162-168. [Editorial]

18. **Hwang TJ**, Sachs RE, Kesselheim AS. Public participation in drafting of the 21st Century Cures Act. *Journal of Law, Medicine, and Ethics* 2017;45(2):212-220.

19. Jain N, **Hwang TJ**, Franklin JM, Kesselheim AS. Association of the priority review voucher with neglected tropical disease drug and vaccine development. *JAMA* 2017;318(4):388-389.

20. **Hwang TJ**, Darrow J, Kesselheim AS. The FDA's expedited pathways and clinical development times for novel therapeutics, 2012-2016. *JAMA* 2017;318(21):2137-2138.

21. **Hwang TJ**, Tomasi PA, Bourgeois FT. Delays in completion and results reporting of clinical trials under the Paediatric Regulation in the European Union: A cohort study. *PLOS Med* 2018;15(3):e1002520.

22. **Hwang TJ**, Tomasi PA, Saint-Raymond A, Bourgeois FT. Availability of paediatric information in European Medicines Agency approvals. *Lancet Child Adolesc Health* 2018;2(5):e9.

23. **Hwang TJ**, Franklin JM, Chen CT, Lauffenburger JC, Gyawali B, Kesselheim AS, Darrow JJ. Efficacy, safety, and regulatory approval of Food and Drug Administration-designated breakthrough and nonbreakthrough cancer medicines. *J Clin Oncol* 2018;36(18):1805-1812.

24. Pregelj L, **Hwang TJ**, Hine DC, Siegel EB, Barnard RT, Darrow JJ, Kesselheim AS. Precision medicines have faster approvals based on fewer and smaller trials than other medicines. *Health Aff* 2018;37(5):724-731.

25. **Hwang TJ**, Kesselheim AS, Gyawali B. Affordability and price increases of new cancer drugs in clinical guidelines, 2007-2016. *JNCI Cancer Spectr* 2018;2(2):pky016.

26. **Hwang TJ**, Kesselheim AS, Vokinger KN. Lifecycle regulation of artificial intelligence- and machine learning-based software devices in medicine. *JAMA* 2019;322(23):2285-2286.

27. **Hwang TJ**, Gyawali B. Association between progression-free survival and patients' quality of life in cancer clinical trials. *Int J Cancer* 2019;144(7):1746-1751.

28. **Hwang TJ**, Orenstein L, Kesselheim AS, Bourgeois FT. Completion rate and reporting of mandatory pediatric postmarketing studies under the Pediatric Research Equity Act. *JAMA Pediatr* 2019;173(1):68-74.

29. **Hwang TJ**, Bourgeois FT, Franklin JM, Kesselheim AS. Impact of the priority review voucher program on drug development for rare pediatric diseases. *Health Aff* 2019;38(2):313-319.

30. Beall RF, **Hwang TJ**, Kesselheim AS. Major events in the life course of new drugs, 2000-2016. *New England Journal of Medicine* 2019;380(11):e12.

31. **Hwang TJ**, Jain N, Lauffenburger JC, Vokinger KN, Kesselheim AS. Analysis of proposed Medicare Part B to Part D shift with associated changes in total spending and patient cost-sharing for prescription drugs. *JAMA Intern Med* 2019;179(3):374-380.

    Crosson FJ, Christianson JB. Managing the cost of Medicare Part B Drugs: implications for the program and beneficiaries. *JAMA Intern Med* 2019;179(3):380-382. [Editorial]

32. Beall RF, **Hwang TJ**, Kesselheim AS. Pre-market development times for biologic versus small-molecule drugs. *Nat Biotechnol* 2019;37(7):708-711.

33. **Hwang TJ**, Dusetzina SB, Feng J, Maini L, Kesselheim AS. Price increases of protected-class drugs in Medicare Part D, relative to inflation, 2012-2017. *JAMA* 2019;322(3):267-269.

34. **Hwang TJ**, Sinha MS, Dave CV, Kesselheim AS. Prescription opioid epidemic and trends in the clinical development of new pain medications. *Mayo Clin Proc* 2019;94(12):2437-2443.

35. Neez E, **Hwang TJ**, Sahoo SA, Naci H. European Medicines Agency's Priority Medicines Scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. *Clin Pharmacol Ther* 2020;107(3):541-552.

36. **Hwang TJ**, Orenstein L, DuBois SG, Janeway KA, Bourgeois FT. Pediatric trials for cancer therapies with targets potentially relevant to pediatric cancers. *J Natl Cancer Inst* 2020;112(3):224-228.

37. Vokinger KN*, **Hwang TJ***, Grischott T, Reichert S, Tibau A, Rosemann T, Kesselheim AS. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. *Lancet Oncol* 2020;21(5):664-670.

38. Molto C*, **Hwang TJ***, Borrell M, Andres M, Gich I, Barnadas A, Amir E, Kesselheim AS, Tibau A. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration. *Cancer* 2020;126(19):4390-4399.

39. **Hwang TJ**, Randolph AG, Bourgeois FT. Inclusion of children in clinical trials of treatments for coronavirus disease 2019 (COVID-19). *JAMA Pediatr* 2020;174(9):825-826.

40. Carmack M, **Hwang T**, Bourgeois FT. Pediatric drug policies supporting safe and effective use of therapeutics in children: a systematic analysis. *Health Aff* 2020;39(10):1799-1805.

41. **Hwang TJ**, Ross JS, Vokinger KN, Kesselheim AS. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study. *BMJ* 2020;371:m3434.

42. Vokinger KN*, **Hwang TJ***, Daniore P, Lee CC, Tibau A, Grischott T, Rosemann TJ, Kesselheim AS. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. *JAMA Oncol* 2021;7(9):e212026.

43. Bujosa A, Molto C, **Hwang TJ**, Tapia JC, Vokinger KN, Templeton AJ, Gich I, Barnadas A, Amir E, Tibau A. Associations with definitive outcomes and clinical benefit of cancer drugs at the time of marketing approval and in the postmarketing period. *J Natl Compr Canc Netw* 2021;1-9.

44. **Hwang TJ**, Qin X, Keating NL, Huskamp HA, Dusetzina SB. Assessment of out-of-pocket costs with rebate pass-through for brand-name cancer drugs under Medicare Part D. *JAMA Oncol* 2022;8(1):155-156.

45. **Hwang TJ**, Vokinger KN, Kesselheim AS. New treatments for migraine-therapeutic ratings and comparative coverage in the US, Canada, and Europe. *JAMA Intern Med* 2022;182(2):101-102.

46. **Hwang TJ**, Feng J, Maini L, Kesselheim AS. Medicaid expenditures and estimated rebates on line extension drugs, 2010-2018. *J Gen Intern Med* 2022;37(14):3769-3771.

47. Vokinger KN, **Hwang TJ**, Carl DL, Laube Y, Ludwig WD, Naci H, Kesselheim AS. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. *Lancet Oncol* 2022;23(4):514-520.

48. Vokinger KN, **Hwang TJ**, Glaus CEG, Kesselheim AS. Therapeutic value assessments of novel medicines in the US and Europe, 2018-2019. *JAMA Netw Open* 2022;5(4):e226479.

49. Naci H, Kyriopoulos I, Feldman WB, **Hwang TJ**, Kesselheim AS, Chandra A. Coverage of new drugs in Medicare Part D. *Milbank Q* 2022;100(2):562-588.

50. **Hwang TJ**, Kesselheim AS, Tibau A, Lee CC, Vokinger KN. Clinical benefit and expedited approval of cancer drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. *JCO Oncol Pract* 2022;18(9):e1522-e1532.

51. **Hwang TJ**, Isaac-Wilkins S, Trinh QD. Trends in launch prices and price increases for new medicines for urological cancers. *J Urol* 2022;208(3):514-516.

52. **Hwang TJ**, Bourgeois FT. New legislation to promote paediatric studies for new cancer medicines. *Lancet Oncol* 2022;23(8):e368-e369.

53. Vokinger KN, Kesselheim AS, Glaus CEG, **Hwang TJ**. Therapeutic value of drugs granted accelerated approval or conditional marketing authorization in the US and Europe From 2007 to 2021. *JAMA Health Forum* 2022;3(8):e222685.

54. **Hwang TJ**, Kesselheim AS, Dusetzina SB. Reforming patient cost sharing for cancer medications in Medicare Part D. *JAMA Oncol* 2022;8(10):1398-1400.

55. Pathak K, Narang C, **Hwang TJ**, Espinoza JC, Bourgeois FT. High-risk therapeutic devices approved by the US Food and Drug Administration for use in children and adolescents from 2016 to 2021. *JAMA Pediatr* 2023;177(1):98-100.

56. Feng J, **Hwang TJ**, Maini L. Profiting from Most-Favored Customer procurement rules: evidence from Medicaid. *American Economic Journal: Economic Policy* 2023;15(2):166-197.

57. Clemans-Cope L, Epstein M, Banthin J, Kesselheim AS, **Hwang TJ**. Estimates of Medicaid and Non-Medicaid net prices of top-selling brand-name drugs incorporating best price rebates, 2015 to 2019. *JAMA Health Forum* 2023;4(1):e225012.

58. **Hwang TJ**, Reaman GH, Bourgeois FT. Clinical trials for paediatric cancers under new legislation in the USA. *Lancet Child Adolesc Health* 2023;7(7):e13.

59. Vokinger KN, Glaus CEG, Kesselheim AS, Serra-Burriel M, Ross JS, **Hwang TJ**. Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study. *BMJ* 2023; 382:e074166.

60. Patel NG, **Hwang TJ**, Woloshin S, Kesselheim AS. Therapeutic value of drugs frequently marketed using direct-to-consumer television advertising, 2015 to 2021. *JAMA Netw Open* 2023;6(1):e2250991.

61. Vokinger KN, Serra-Burriel M, Glaus CEG, Rohr UP, **Hwang TJ**, Dalla Torre di Sanguinetto S, Kesselheim AS. Regulatory review duration and differences in submission times of drugs in the United States and Europe, 2011 to 2020. *Ann Intern Med* 2023;176(10):1413-1418.

62. **Hwang TJ**, Davies BJ, Preston MA. Advancing patient-centered outcomes and equity in clinical trials for BCG-unresponsive nonmuscle invasive bladder cancer. *JAMA Oncol* 2023;9(11):1491-1492.

63. Tibau A, **Hwang TJ**, Molto C, Avorn J, Kesselheim AS. Clinical value of molecular targets and FDA-approved genome-targeted cancer therapies. *JAMA Oncol* 2024;10(5):634-641.

64. Tibau A, **Hwang TJ**, Avorn J, Kesselheim AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. *BMJ* 2024;386:e079126.

65. Liu ITT, **Hwang TJ**, Kesselheim AS. Testing of new drugs approved from 2015 through 2021 under the US Pediatric Research Equity Act. *JAMA* 2024;332(17):1482-1484.

66. Tibau A, **Hwang TJ**, Romano A, Borrell M, Gich I, Molto C, Kesselheim AS. Factors in time to full approval or withdrawal for anticancer medicines granted accelerated approval by the FDA. *JAMA Netw Open*

2025;8(3):e252026.

67. **Hwang TJ**, Keating NL, Dusetzina SB. Biologic drugs and Medicare price negotiation. *New England Journal of Medicine* 2025;393(1):6-9.

68. **Hwang TJ**, Trinh QD, Vokinger KN. The risks of pharmaceutical tariffs for generic drug availability. *New England Journal of Medicine* 2025;393(13):1252-1253.

69. **Hwang TJ**, Vokinger KN. Clinical benefit and the Trump administration's cancer medicine reforms. *Lancet Oncol* 2026;27(3):280-281.

70. **Hwang TJ**, Tibau A, Kesselheim AS, Vokinger KN. Implications of Medicare negotiation and Most-Favored-Nation pricing for cancer medicine costs. *JAMA Health Forum* 2026;7(5):e260509.

71. **Hwang TJ**, Clemans-Cope L, Kesselheim AS. Savings under Most-Favored-Nation pricing for prescription drugs in Medicaid. *JAMA*. Published online July 13, 2026. doi:10.1001/jama.2026.9973

**Other peer-reviewed scholarship**

1. **Hwang TJ**, Keshavjee S. Global financing and long-term technical assistance for multidrug-resistant tuberculosis: Scaling up access to treatment. *PLOS Medicine* 2014;11(9):e1001738.

2. **Hwang TJ**, Bourgeois FT. New regulatory paradigms for innovative drugs to treat pediatric diseases. *JAMA Pediatrics* 2014;168(10):879-880.

3. **Hwang TJ**, Powers JH, Carpenter D, Kesselheim AS. Accelerating innovation in rapid diagnostics and targeted antibacterials. *Nature Biotechnology* 2015;33(6):589-590.

4. **Hwang TJ**, Carpenter D, Kesselheim AS. Reimbursement incentives for antibiotics. *Science Translational Medicine* 2015;7(276):276fs9.

5. **Hwang TJ**, Ciolino JB. Retinal implants and Medicare reimbursement policies for breakthrough treatments in ophthalmology. *JAMA Ophthalmology* 2015;133(4):373-374.

6. **Hwang TJ**, Kiang CJ, Paul M. Surgical applications of three-dimensional printing and precision medicine. *JAMA Otolaryngology—Head and Neck Surgery* 2015;141(4):305-306.

7. **Hwang TJ**, Kesselheim AS. Leveraging novel and existing pathways to approve new therapeutics to treat serious drug-resistant infections. *American Journal of Law & Medicine* 2016;42(2):429-450.

8. **Hwang TJ**, LaMattina JL. Measuring the value of new medications and implications for Medicare's proposed Part B drug payment model. *JAMA Oncology* 2016;2(9):1125-1126.

9. **Hwang TJ**, Kesselheim AS. Challenges in the development of novel cardiovascular therapies. *Clin Pharmacol Ther* 2017;102(2):194-196.

10. Bourgeois FT, **Hwang TJ**. The Pediatric Research Equity Act moves into adolescence. *JAMA* 2017;317(3):259-260.

11. **Hwang TJ**, Kesselheim AS, Sarpatwari A. Value-based pricing and state reform of prescription drug costs. *JAMA* 2017;318(7):609-610.

12. Bourgeois FT, **Hwang TJ**. Improving the study of new medicines for children with rare diseases. *JAMA*

*Pediatr* 2018;172(1):7-9.

13. **Hwang TJ**, Vokinger KN, Sachs RE. Evaluating new rules on transparency in cancer research and drug development. *JAMA Oncol* 2019;5(4):461-462.

14. Kesselheim AS, **Hwang TJ**, Avorn J. Paying for prescription drugs in the new administration. *JAMA* 2021; 325(9):819-820.

15. **Hwang TJ**, Vokinger KN. New EU regulation on health technology assessment of cancer medicines. *Lancet Oncol* 2022;23(2):e58.

16. **Hwang TJ**, Trinh QD, Tibau A, Vokinger KN. Reforms to accelerated approval of new medicines: long overdue. *Lancet* 2022;400(10349):357-358.

17. **Hwang TJ**, Kesselheim AS, Rome BN. New reforms to prescription drug pricing in the US: opportunities and challenges. *JAMA* 2022;328(11):1041-1042.

18. **Hwang TJ**, Kesselheim AS, Vokinger KN. Reforming the World Health Organization's Essential Medicines List: essential but unaffordable. *JAMA* 2022;328(18):1807-1808.

19. **Hwang TJ**, Trinh QD, Sokolov E. Safe and equitable use of clinical decision support systems. *Lancet* 2024;404(10458):1100-1101.

20. **Hwang TJ**, Dasgupta P. Urgently clarify how AI can be used in medicine under new EU law. *Nature* 2024;632(8027):985.

21. **Hwang TJ**, Maini L. Challenges in delivering Most-Favored-Nation pricing for prescription drugs in the US. *JAMA* 2025;334(9):763-764.

22. Sachs RE, **Hwang TJ**, Dusetzina SB. The role of combination drugs in the Medicare Drug Price Negotiation Program. *JAMA* 2025;334(9):759-760.

23. Carpenter D, **Hwang TJ**, Kesselheim AS. Flaws in the FDA's new priority voucher program. *New England Journal of Medicine* 2025;393(17):1662-1664.

24. **Hwang TJ**, Choueiri TK, Vokinger KN. New Medicare payment policy on drug shortages. *JAMA Health Forum* 2026;7(2):e256923.

25. **Hwang TJ**, Clemans-Cope L, Kesselheim AS. Reforming payment for clinician-administered drugs - Most-Favored-Nation pricing in Medicare Part B. *New England Journal of Medicine* 2026;394(18):1774-1777.